TargetBeta
KAT6A
lysine acetyltransferase 6A · also MOZ, ZNF220, RUNXBP2, MYST3 · PHD finger proteins
8 programs in company-led studies act on KAT6A, from 7 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| prifetrastat | Pfizer | phase 3 | 105 running | KAT6B | the company's pipeline |
| KAT6A/B Inhibitor BG-75202rule | BeOne Medicines | phase 1 | 22 running | KAT6B | NCIt |
| HRS-2189 | Jiangsu HengRui Medicine | phase 1 | 21 running | KAT6B | the company's pipeline |
| HLX97 | Fosun Pharma | phase 1 | 11 running | KAT6B | the company's pipeline |
| KAT6 Inhibitor OP-3136rule | Olema Pharmaceuticals | phase 1 | 11 running | KAT6B | NCIt |
| KAT6/KAT7 Inhibitor IDE574rule | IDEAYA Biosciences | phase 1 | 11 running | KAT6B, KAT7 | NCIt |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 11 running | KAT6B, KAT7 | NCIt |
| PRT13722rule | Prelude Therapeutics | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Breast Neoplasms, 3 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Neoplasms, 1 program
- Renal Insufficiency, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 8, 2026prifetrastat · Pfizer · phase 3 · NCT07721402
- May 30, 2027KAT6 Inhibitor OP-3136 · Olema Pharmaceuticals · phase 1 · NCT06784193
- Mar 2028HLX97 · Fosun Pharma · phase 1 · NCT07480681
- Sep 30, 2028KAT6A/B Inhibitor BG-75202 · BeOne Medicines · phase 1 · NCT07619287
- Oct 31, 2028PRT13722 · Prelude Therapeutics · phase 1 · NCT07905001
- Apr 14, 2029KAT6/KAT7 Inhibitor PF-08032562 · Pfizer · phase 1 · NCT07318805
- Dec 31, 2029KAT6/KAT7 Inhibitor IDE574 · IDEAYA Biosciences · phase 1 · NCT07540572
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.